Mr. Iwicki stated, “I am proud of the work we have done at KALA utilizing our MSC-S platform, and I am very excited about the potential of our lead product candidate, KPI-012 for the treatment of PCED ...

In a recent virtual meeting, GRI Bio, Inc. (NASDAQ:GRI), a pharmaceutical company whose stock has declined nearly 98% over the past year according to InvestingPro data, received stockholder approval ...

New York, USA, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment ...

GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of ...

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

They call themselves Speed to Market, a group of life sciences and real estate professionals who find, build, and sell manufacturing space for biotech employers around Philadelphia. During the COVID ...

She currently holds the position of Chief Financial Officer at GRI Bio, Inc., a biotechnology firm focused on developing cell modulators for treating inflammatory, fibrotic, and autoimmune ...

Cabaletta Bio’s proactive approach to engage with the FDA for transitioning to registrational trials indicates a clear path forward. The company’s valuation is supported by a risk-adjusted ...

GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of ...